|
1
|
Heist RS, Mino-Kenudson M, Sequist LV,
Tammireddy S, Morrissey L, Christiani DC, Engelman JA and Iafrate
AJ: FGFR1 amplification in squamous cell carcinoma of the lung. J
Thorac Oncol. 7:1775–1780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society: Cancer Facts and
Figures 2018. Atlanta, Ga: American Cancer Society; 2018, Available
online. Last accessed. April 27–2018
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alberg AJ, Brock MV and Samet JM:
Epidemiology of lung cancer: Looking to the future. J Clin Oncol.
23:3175–3185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bondarenko I, Luft A,
Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H,
Cuillerot JM and Reck M: Ipilimumab in combination with paclitaxel
and carboplatin as first-line treatment in stage IIIB/IV
non-small-cell lung cancer: Results from a randomized,
double-blind, multicenter phase II study. J Clin Oncol.
30:2046–2054. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gibbons DL, Byers LA and Kurie JM:
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stilgenbauer S, Schnaiter A, Paschka P,
Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M,
et al: Gene mutations and treatment outcome in chronic lymphocytic
leukemia: Results from the CLL8 trial. Blood. 123:3247–3254. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosenfeld MR, Malats N, Schramm L, Graus
F, Cardenal F, Viñolas N, Rosell R, Torà M, Real FX, Posner JB and
Dalmau J: Serum anti-p53 antibodies and prognosis of patients with
small-cell lung cancer. J Natl Cancer Inst. 89:381–385. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Azad Behnam B, Lisok A, Chatterjee S,
Poirier JT, Pullambhatla M, Luker GD, Pomper MG and Nimmagadda S:
Targeted imaging of the atypical chemokine receptor 3 (ACKR3/CXCR7)
in human cancer xenografts. J Nucl Med. 57:981–988. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng CX, Gu ZH, Han B, Zhang RX, Pan CM,
Xiang Y, Rong XJ, Chen X, Li QY and Wan HY: Whole-exome sequencing
to identify novel somatic mutations in squamous cell lung cancers.
Int J Oncol. 43:755–764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quintanal-Villalonga Á, Carranza-Carranza
A, Meléndez R, Ferrer I, Molina-Pinelo S and Paz-Ares L: Prognostic
role of the FGFR4-388Arg variant in lung squamous-cell carcinoma
patients with lymph node involvement. Clin Lung Cancer.
18(667-674): e12017.PubMed/NCBI
|
|
13
|
Lu YF, Goldstein DB, Angrist M and
Cavalleri G: Personalized medicine and human genetic diversity.
Cold Spring Harb Perspect Med. 4:a0085812014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lorenzi PL, Claerhout S, Mills GB and
Weinstein JN: A curated census of autophagy-modulating proteins and
small molecules: Candidate targets for cancer therapy. Autophagy.
10:1316–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao H, Duan J, Lin D, Shugart YY, Calhoun
V and Wang YP: Sparse representation based biomarker selection for
schizophrenia with integrated analysis of fMRI and SNPs.
Neuroimage. 102:220–228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanchez-Palencia A, Gomez-Morales M,
Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R and Fárez-Vidal ME:
Gene expression profiling reveals novel biomarkers in nonsmall cell
lung cancer. Int J Cancer. 129:355–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dehan E, Ben-Dor A, Liao W, Lipson D,
Frimer H, Rienstein S, Simansky D, Krupsky M, Yaron P, Friedman E,
et al: Chromosomal aberrations and gene expression profiles in
non-small cell lung cancer. Lung Cancer. 56:175–184. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kohavi R: A study of cross-validation and
bootstrap for accuracy estimation and model selectionProceedings of
the Fourteenth International Joint Conference on Artificial
Intelligence. San Mateo, CA: Morgan Kaufmann; 2. pp. 1137–1143.
1995
|
|
19
|
Gan TQ, Xie ZC, Tang RX, Zhang TT, Li DY,
Li ZY and Chen G: Clinical value of miR-145-5p in NSCLC and
potential molecular mechanism exploration: A retrospective study
based on GEO, qRT-PCR, and TCGA data. Tumour Biol.
39:10104283176916832017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt
A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, et al: Mutations in
the DDR2 kinase gene identify a novel therapeutic target in
squamous cell lung cancer. Cancer Discov. 1:78–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weiss J, Sos ML, Seidel D, Peifer M,
Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A,
et al: Frequent and focal FGFR1 amplification associates with
therapeutically tractable FGFR1 dependency in squamous cell lung
cancer. Sci Transl Med. 2:62ra932010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sos ML and Thomas RK: Genetic insight and
therapeutic targets in squamous-cell lung cancer. Oncogene.
31:4811–4814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Loeb LA, Loeb KR and Anderson JP: Multiple
mutations and cancer. Proc Natl Acad Sci USA. 100:776–781. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ramsey MR, Wilson C, Ory B, Rothenberg SM,
Faquin W, Mills AA and Ellisen LW: FGFR2 signaling underlies p63
oncogenic function in squamous cell carcinoma. J Clin Invest.
123:3525–3538. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ling B and Wei GZ: p53: Structure,
function and therapeutic applications. J Cancer Mol. 2:141–153.
2006.
|
|
26
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yip PY: Phosphatidylinositol
3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR)
signaling pathway in non-small cell lung cancer. Transl Lung Cancer
Res. 4:165–176. 2015.PubMed/NCBI
|
|
28
|
Davies H, Hunter C, Smith R, Stephens P,
Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, et
al: Somatic mutations of the protein kinase gene family in human
lung cancer. Cancer Res. 65:7591–7595. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kurishima K, Satoh H, Kagohashi K, Homma
S, Nakayama H, Ohara G, Ishikawa H and Hizawa N: Patients with lung
cancer with metachronous or synchronous gastric cancer. Clin Lung
Cancer. 10:422–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Genç B, Solak A, Sahin N and Gülşen A:
Metastasis to the male breast from squamous cell lung carcinoma.
Case Rep Oncol Med. 2013:5939702013.PubMed/NCBI
|
|
31
|
Zhang J, Zhang L, Su X, Li M, Xie L,
Malchers F, Fan S, Yin X, Xu Y, Liu K, et al: Translating the
therapeutic potential of AZD4547 in FGFR1-amplified non-small cell
lung cancer through the use of patient-derived tumor xenograft
models. Clin Cancer Res. 18:6658–6667. 2012. View Article : Google Scholar : PubMed/NCBI
|
